BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp Cuts Position in Thermo Fisher Scientific Inc. $TMO

Key Points

• British Columbia Investment Management Corp reduced its stake in Thermo Fisher Scientific Inc. by 16.2% during the first quarter, now owning approximately 170,429 shares valued at $84.8 million.
• Several hedge funds, including Mondrian Investment Partners LTD, have made significant adjustments to their holdings, with Mondrian increasing its stake by 146.1% and now owning 214,506 shares.
• Thermo Fisher Scientific recently announced a quarterly dividend of $0.43 per share with a dividend yield of 0.3%, payable on October 15th.

BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp lowered its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 16.2% in the first quarter, according to its most recent 13F filing with the SEC. The fund owned 170,429 shares of the medical research company's stock after selling 32,972 shares during the period. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp's holdings in Thermo Fisher Scientific were worth $84,805,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Haverford Trust Co grew its position in Thermo Fisher Scientific by 5.4% during the first quarter. Haverford Trust Co now owns 220,235 shares of the medical research company's stock valued at $109,589,000 after buying an additional 11,275 shares during the period. Douglass Winthrop Advisors LLC raised its position in Thermo Fisher Scientific by 2.2% during the first quarter. Douglass Winthrop Advisors LLC now owns 25,878 shares of the medical research company's stock worth $12,877,000 after acquiring an additional 545 shares during the period. Sax Wealth Advisors LLC increased its stake in shares of Thermo Fisher Scientific by 5.6% during the first quarter. Sax Wealth Advisors LLC now owns 625 shares of the medical research company's stock worth $311,000 after purchasing an additional 33 shares in the last quarter. AlphaQuest LLC raised its holdings in shares of Thermo Fisher Scientific by 21,725.0% during the first quarter. AlphaQuest LLC now owns 2,619 shares of the medical research company's stock valued at $1,303,000 after acquiring an additional 2,607 shares during the last quarter. Finally, Allstate Corp lifted its holdings in Thermo Fisher Scientific by 22.3% in the 1st quarter. Allstate Corp now owns 13,911 shares of the medical research company's stock valued at $6,922,000 after purchasing an additional 2,540 shares in the last quarter. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Stock Down 0.0%

NYSE TMO traded down $0.01 during trading on Wednesday, reaching $488.47. 1,286,715 shares of the company's stock were exchanged, compared to its average volume of 2,460,395. The company has a 50 day moving average price of $446.71 and a two-hundred day moving average price of $455.47. The stock has a market cap of $184.45 billion, a P/E ratio of 28.25, a price-to-earnings-growth ratio of 2.62 and a beta of 0.74. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $627.88. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The firm had revenue of $10.86 billion during the quarter, compared to the consensus estimate of $10.68 billion. During the same period in the prior year, the company posted $5.37 earnings per share. The firm's quarterly revenue was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be given a dividend of $0.43 per share. The ex-dividend date is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.4%. Thermo Fisher Scientific's dividend payout ratio (DPR) is 9.95%.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on TMO. Raymond James Financial reissued an "outperform" rating and issued a $535.00 price objective (up previously from $525.00) on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Wall Street Zen downgraded shares of Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a report on Sunday, August 10th. William Blair began coverage on shares of Thermo Fisher Scientific in a research report on Monday, August 18th. They set an "outperform" rating on the stock. UBS Group upped their target price on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the stock a "neutral" rating in a research note on Thursday, July 24th. Finally, HSBC restated a "hold" rating and issued a $510.00 price target on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Sixteen investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $593.00.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $500.96, for a total value of $5,009,600.00. Following the transaction, the chief executive officer directly owned 115,174 shares in the company, valued at approximately $57,697,567.04. This trade represents a 7.99% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Gianluca Pettiti sold 400 shares of the company's stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $479.98, for a total value of $191,992.00. Following the sale, the executive vice president owned 22,367 shares of the company's stock, valued at $10,735,712.66. This trade represents a 1.76% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 28,896 shares of company stock valued at $13,603,438. 0.33% of the stock is owned by company insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.